Analytical Data
-
Gene name
CMRF35-like molecule 1
- Application
-
Alternative Names
CD300 antigen-like family member F CD_antigen: CD300f
-
Species
Rat
-
Source
E. coli
-
Tag
N- His-SUMO & C- Myc
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q566E6
-
Expression Region
19-181aa
-
Molecular Weight
38.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CMRF35-like molecule 1 (CLM-1) is a member of the CMRF35 family, which is characterized by its role in immune regulation. Research into CLM-1 has gained traction due to its potential implications in modulating immune responses, particularly in the context of autoimmune diseases and cancer. This protein acts as an inhibitory receptor on immune cells, influencing their activation and function. Its expression is often upregulated in certain pathological conditions, suggesting a role in tumor microenvironments where it may contribute to immune evasion by cancer cells. The study of CLM-1 is crucial for understanding its signaling pathways and interactions with ligands, which may lead to the development of targeted therapies aimed at restoring immune function. The generation of recombinant CLM-1 proteins allows for detailed mechanistic studies and the assessment of its potential as a therapeutic target. These insights could pave the way for novel treatments that enhance anti-tumor immunity or alleviate inappropriate immune responses in autoimmune disorders. Consequently, the characterization and functional analysis of recombinant CLM-1 not only deepen our understanding of immune regulation but also contribute to the broader field of immunotherapy research.
